The US Food and Drug Administration’s (FDA’s) Office of Compliance
will be elevated to a “Super Office” within the agency’s Center for
Drug Evaluation and Research (CDER). The move was reported to be under
consideration a few months ago and has now been made official,
according to an internal letter to staff from CDER Director Janet
Woodcock. “Given CDER/OC’s expanding role, size, and importance in
achieving the Agency’s mission of safeguarding the US drug supply, this
structural transition makes a great deal of sense,” Woodcock wrote in
the letter. “The reorganization will enable Compliance to align its
scientific, technical, and legal capabilities with closely related
program areas, leveraging our resources and maximizing its ability to
achieve its public health mission.” The Office of Compliance will
oversee subordinate offices, including four new offices.
Read more: